In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …

Introduction: Adenoviruses (Ads) have attracted researchers from across the disciplines for
several reasons. Their ability to recombine with and express the heterologous genes …

Adoptive cell therapy holds much promise in the treatment of cancer but results in solid
tumors have been modest. The notable exception is tumor-infiltrating lymphocyte (TIL) …

Simple Summary Glioblastoma (GBM) is the most frequent and aggressive primary brain
tumor. Despite multimodal treatment, the prognosis of GBM patients remains very poor …

Background Ovarian cancers often contain significant numbers of tumor-infiltrating
lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT) …

Oncolytic virotherapy has currently emerged as a powerful therapeutic approach in cancer
treatment. Although the history of using viruses goes back to the early 20th century, the …

Resistance to therapy is a frequently observed phenomenon in the treatment of cancer, and
as with other cancer therapeutics, therapies based on oncolytic viruses also face the …

Resistance to oncolytic virotherapy is frequently associated with failure of tumor cells to get
infected by the virus. Dimethyl fumarate (DMF), a common treatment for psoriasis and …

Twenty-five patients with chemotherapy refractory cancer were treated with a fully serotype 3-
based oncolytic adenovirus Ad3-hTERT-E1A. In mice, Ad3 induced higher amounts of …

Oncolytic virotherapy has advanced since the days of its conception but therapeutic efficacy
in the clinics does not seem to reach the same level as in animal models. One reason is …